Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS

In contrast to cutaneous melanoma, there is no evidence that BRAF mutations are involved in the activation of the mitogen-activated protein kinase (MAPK) pathway in uveal melanoma, although there is increasing evidence that this pathway is activated frequently in the latter tumours. In this study, we performed mutation analysis of the RAS and BRAF genes in a panel of 11 uveal melanoma cell lines and 19 primary uveal melanoma tumours. In addition, Western blot and immunohistochemical analyses were performed on downstream members of the MAPK pathway in order to assess the contribution of each of these components. No mutations were found in any of the three RAS gene family members and only one cell line carried a BRAF mutation (V599E). Despite this, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), ERK and ELK were constitutively activated in all samples. These data suggest that activation of the MAPK pathway is commonly involved in the development of uveal melanoma, but occurs through a mechanism different to that of cutaneous melanoma.

Keywords: MAPK pathway; uveal melanoma; BRAF; RAS; mutation

Uveal melanoma is the most common primary intraocular tumour in adults, with an annual incidence of 6–8 new cases per million among Caucasian populations. Up to half of all patients die from metastatic disease (Diener-West et al, 1992). In spite of several known prognostic markers (pathologic and genetic), such as tumour cell type, diameter, localisation and cytogenetic abnormalities, little is known about specific genes associated with predisposition and progression in uveal melanoma (Mooy and de Jong, 1996; Sisley et al, 1997). Notable exceptions are hypermethylation of CDKN2A, which is more common in tumours from patients who develop metastatic disease (van der Velden et al, 2001), and germline BRCA2 gene mutations, which occur in 3% of patients younger than 50 years of age (Scott et al, 2002). Hence, the search for other genes and molecular pathways involved in uveal melanoma development is of great significance. In contrast to uveal melanoma, the influence of specific pathways in cutaneous melanoma, which shares the same embryonic origin, is better defined. For instance, the tumour suppressor gene PTEN, encoding a dual-specific phosphatase and a member of the PI3-AKT pathway, plays a major role in the pathogenesis of cutaneous melanoma (Guldberg et al, 1997; Stahl et al, 2003), whereas no mutations in this gene have been found in uveal melanoma (Naus et al, 2000).

Recently, the RAS-RAF-MEK-ERK or mitogen-activated protein kinase (MAPK) pathway has been found to play an important role in melanocytic neoplasia (Cohen et al, 2002; Satyamoorthy et al, 2003). Activation of this pathway in cutaneous melanocytes has been shown to occur by a variety of mechanisms, including autocrine growth factor stimulation and mutation of the RAS or BRAF genes. Of three RAS genes found to be activated by mutation in human tumours, NRAS (neuroblastoma RAS viral (v-ras) oncogene homologue) is most commonly mutated in cutaneous melanomas (van Elsas et al, 1996). In the active GTP-bound state, RAS activates a number of downstream signalling cascades involved in controlling cell growth and behaviour. Initially, RAS interacts with and activates the serine/threonine protein kinase BRAF that acts in the MAPK pathway to transduce regulatory signals from RAS to mitogen-activated protein kinase/extracellular signal-related kinase kinase (MEK1/2). The signal transducer MEK1/2 phosphorylates extracellular signal-regulated kinase (ERK1/2, p44/42), leading to the activation of these kinases, which in turn activate a variety of transcription factors, including ELK1, again through phosphorylation. It has emerged that BRAF (v-raf murine sarcoma viral oncogene homologue B1) is very frequently activated by mutation in cutaneous melanomas (Brose et al, 2002; Davies et al, 2002; Alsina et al, 2003; Dong et al, 2003; Gorden et al, 2003; Kumar et al, 2003a, b; Maldonado et al, 2003; Omholt et al, 2003; Pollock et al, 2003; Rimoldi et al, 2003; Satyamoorthy et al, 2003; Weber et al, 2003; Cohen et al, 2004; Reifenberger et al, 2004; Shimozaki et al, 2004; Tsao et al, 2004). The frequency of BRAF mutations varies from 8 to 83% depending...
on the anatomic site of the lesion and its histogenic subtype. Notably, the frequency of BRAF mutations is also high in benign melanocytic naevi (Dong et al, 2003; Pollock et al, 2003; Uribe et al, 2003; Yazdi et al, 2003), indicating that constitutive activation of the MAPK pathway is an early event in melanoma-genesis. All BRAF mutations in cutaneous pigmented neoplasms occur within the kinase domain. The most frequently found mutation in BRAF (V599E) consists of a 1796T→A transversion in exon 15 (Davies et al, 2002). Various other mutations have been described in this exon in melanocytic tumours (V599D (Brose et al, 2002; Davies et al, 2002; Pollock et al, 2003); V599K (Pollock et al, 2003, Uribe et al, 2003); V599R (Pollock et al, 2003); K600E (Brose et al, 2002, Satyamoorthy et al, 2003)). All other mutations have been described in exon 11. The latter consist of a 1352A→C transversion (K438Q) (Brose et al, 2002), a 1402G→A transition (G468R) and a 1402/1403GG tandem transversion (Gorden et al, 2003), a 1394G→A transition (G465E) and a 1394G→C transversion (G465A) (Davies et al, 2002). Furthermore, it is not surprising that since they activate the same pathway, mutations in NRAS and BRAF are almost mutually exclusive (Brose et al, 2002; Davies et al, 2002; Alsinia et al, 2003; Dong et al, 2003; Gorden et al, 2003; Kumar et al, 2003a, b; Omholt et al, 2003; Pollock et al, 2003; Satyamoorthy et al, 2003; Reifenberger et al, 2004; Tsao et al, 2004).

Since cutaneous and uveal melanoma both arise from neural crest-derived melanocytes, we sought to assess whether the MAPK pathway was similarly activated in melanoma of the uvea. For this purpose, we selected two uveal melanoma cell lines, Ocm 1 and Ocm 3, from a panel of 14 uveal melanoma cell lines established in our own laboratory (de Waard-Siebinga et al, 1995). The melanoma cell lines were cultured in RPMI 1640 (Gibco, Paisley, Scotland) medium, supplemented with 2.5% L-glutamine (Gibco), 2% penicillin/streptomycin and 10% FBS (HyClone, Logan, UT, USA). All cell cultures were incubated at 37°C in a humidified 5% CO2 atmosphere. In addition, we analysed 19 primary frozen uveal melanomas. Of the primary tumours, eight were located in the choroid and 11 in both the choroid and ciliary body. Four of these samples showed a spindle cell type, one an epithelioid cell type and 14 had a mixed population of cells. All samples were derived from tumours with a diameter greater than 12 mm and a prominence greater than 6 mm. The research protocol followed the tenets of the Declaration of Helsinki (World Medical Association Declaration of Helsinki 1964; ethical principles for medical research involving human subjects).

Sequencing
DNA was extracted from each cell line using an adaptation of the salting-out method (Miller et al, 1988). Primers used to amplify parts of the BRAF and NRAS genes are given in Table 1. Reactions for BRAF contained 200 ng of DNA, QIAGEN (Hilden, Germany) PCR buffer (10× concentrated), containing Tris-Cl, KCl, (NH4)2SO4, 15 mM MgCl2, 1 mM dNTPs, 15 mm MgCl2; pH 8.7), Q solution (PCR enhancer), and 1.5 units of Taq polymerase (Promega, Madison, WI, USA). The PCR primers for BRAF and NRAS genes are given in Table 1.

Table 1 PCR primers for BRAF, NRAS, KRAS and HRAS genes

| Samples     | Gene | Exon/region | Primer name | Primer sequence (5’ → 3’) | Product size (bp) |
|-------------|------|-------------|-------------|---------------------------|------------------|
| Cell lines  | BRAF | 11          | x1F         | CTCCTAGGCATATAGGTAATGAC   | 360              |
| (DNA)       |      |             | x1R         | GAGTCCCGACTGTGGATGAC      |                  |
|             |      |             | x1F         | CTAAGAGGAAAGATGAGTCTATG   |                  |
|             |      |             | x1R         | CTAGTAACTCACGAGCTTCAG     | 328              |
|             | NRAS| 1           | x1F         | CTGGTTTCAACAGGGTTCTGTG    | 567              |
|             |     |             | x1R         | TGCATTCAATCATTGCTGTC      |                  |
|             | NRAS| 2           | x2F         | CACACCCCCAGAGTCTTAC       | 438              |
|             |     |             | x2R         | GTAACGTTTACCCCTGAGCA      |                  |
|             | HRAS| 1           | x1F         | GCCCGAGGACCCCTGAGCA       | 232              |
|             |     |             | x1R         | AGCCCCATCTGTGCTGGA        |                  |
|             | NRAS| 2           | x2F         | AGAGGCTGGCTGTAATGAC       | 344              |
|             |     |             | x2R         | ACATGCCAGAGAGGAGCAG       |                  |
|             | KRAS| 1           | x1F         | GATTTCCTAGAgGAGCCG        | 199              |
|             |     |             | x1R         | GTCCGGTCCCCTACCTCTCTCC    |                  |
|             | KRAS| 2           | x2F         | GCCCTGTGGACAAAATGCTG      |                  |
|             |     |             | x2R         | TATTGTTGACGTATCTGTCAC     | 120              |
| Tumours     | BRAF| 11 – 15     | F           | TCAACCAAGGTGTTGTACTGC     | 696              |
| (cDNA)      |      |             | R           | GATGACTTCTGGTGCCATTGC     |                  |
|             | NRAS| F           | R           | GGGGTCTCCCAACATTTTCC      | 390              |
|             | HRAS| F           | R           | CAGGAGAAGCTGAGAAAATGCTG   | 968              |
|             | KRA| F           | R           | AGGCCCTGGCTAAAGTACTG      |                  |
|             | S   |             |             | TCAATCTGTATTGCTGAAGCT     | 519              |
20 pmol μl⁻¹ of each primer, 2 μM of each dNTP and 1.25 U of QIAGEN Taq polymerase. Amplification involved 35 cycles of denaturation at 94 °C for 45 s, annealing at 56 °C for 90 s, and extension at 72 °C for 90 s. An initial 12 min denaturation step at 94 °C and a final 3 min extension at 72 °C were also used. For the RAS genes, DNA was amplified using QIAGEN Taq polymerase as described above, but PCR involved a ‘touchdown’ thermal cycling routine of two cycles at each annealing temperature, decreasing by steps of 2 °C, followed by 25 cycles at the lowest temperature. Each cycle consisted of denaturation at 94 °C for 45 s, annealing at 65 – 57 °C for 90 s and extension at 72 °C for 90 s. An initial 12 min denaturation at 94 °C and a final 3 min extension at 72 °C were also employed.

From 19 fresh frozen uveal melanoma samples, total RNA was extracted with RNeasy kits as described by the manufacturer (QIAGEN). RNA was primed with random primers and reverse transcribed into cDNA in a 20 μl reaction volume containing 200 U Superscript II (MMV) reverse transcriptase (Invitrogen, Inc., Breda, The Netherlands). PCR primers used for amplifying parts of the BRAF and RAS genes in the primary tumour samples are also listed in Table 1. A touchdown PCR procedure for BRAF was followed as described above and a fixed annealing temperature of 57 °C with a total of 38 cycles was used for the RAS genes followed by a final elongation step of 10 min.

PCR products of all samples were electrophoresed through 1.5% TAE/agarose gels stained with ethidium bromide, excised and purified using a QIAGEN QIAquick Gel Extraction Kit. The RAS and BRAF PCR products were sequenced using Applied Biosystems (ABI) BigDye version 3 reagents according to the manufacturer’s instructions using 3.2 pmol μl⁻¹ of primer. Sequencing products were precipitated using 75% isopropanol and were run on an ABI 377 automated sequencer (PE Applied Biosystems, Foster City, CA, USA).

**Western blot analysis**

Protein lysates from the uveal melanoma cell lines were separated on 12.5% SDS–PAGE gels and the proteins transferred to Hybond-Polyvinylidene fluoride membranes (Amersham biosciences, Buckinghamshire, UK). After blocking with 5% skim milk in PBS-Tween solution, the membranes were probed overnight at 4 °C with the following primary antibodies specific to each antigen: phospho-MEK1/2 (dilution 1:1000), phospho-ERK1/2 (pH4/42) (#9106, dilution 1:5000), total ERK1/2 (#9102, dilution 1:1000) and phospho-ELK1 (dilution 1:1000) antibody (all from Cell Signalling Technology, Hertfordshire, UK). An antibody against actin (Santa Cruz Biotechnology, California, USA) was used as a loading control. Membranes were then incubated with horseradish peroxidase-conjugated IgG anti-mouse, anti-rabbit or anti-goat secondary antibodies for 1 h at room temperature to visualise protein bands.

**Immunohistochemistry**

Acetone-fixed 10 μm sections of 19 fresh frozen uveal melanomas were washed three times in PBS (pH = 7.2) and were incubated with anti-ERK1/2 and anti-phospho-ERK 1/2 antibodies (Cell Signalling Technology, Beverly MA, USA, #9102 and #9106, respectively), both diluted 1:100 in PBS with 1% BSA and 2% normal human serum (NHS) at 4 °C. The sections were washed three times and incubated with cy3-conjugated AffiniPure goat anti-rabbit IgG or with cy3-conjugated AffiniPure rabbit anti-mouse IgG (Jackson ImmunoResearch, West Grove PA, USA #111-165-003 and #315-165-003) both diluted 1:500, respectively, during 1 h at room temperature. Sections were rinsed with PBS three times and incubated for 20 min with Alexa Fluor 647 Phalloidin (Molecular Probes, Leiden, The Netherlands, #A2287) at a 1:40 dilution. Sections are washed three times with PBS. A nuclear staining was preformed by incubating the sections for 5 min with 4’,6-diamidino-2-phenylindole dilactetate (DAPI, Molecular Probes, Leiden, The Netherlands, #D-3571) 1:500. Sections were rinsed briefly in PBS and imbedded with Vectashield (Veta Shield H1000, Brunschwig, Amsterdam, The Netherlands). For each specimen, the fluorescence of cy3 was determined in three different microscope fields (Leica DMRXA microscope, Leica Microsystems, Rijswijk, The Netherlands). No background fluorescence of cy3 was observed. The number of positively stained tumour cells was estimated for the two antibodies and expressed as the percentage of the total number of tumour cells in the analysed section. Percentages were then categorised as either negative <5% (+/−), very weakly positive 5–25% (+), weakly positive 26–50% (+/+), moderately positive 51–75% (+/++) or highly positive 76–100% (+++/+++).

The slides were examined by two observers independently. Interobserver disagreement did not exceed one category.

**RESULTS**

**Mutation analysis**

Of the 11 uveal melanoma cell lines under study, only one cell line (Ocm 1) carried a BRAF mutation, the common V599E (also described by Calipel et al and Kilic et al). All primary tumour specimens were wild type for BRAF. No mutations were found in the NRAS, HRAS or KRAS genes, in both the cell lines and primary tissue.

**Western blotting**

In order to assess the level of expression and the activation (by phosphorylation) of members of the MAPK pathway downstream of RAS and BRAF, Western blot analysis was performed on uveal melanoma cell lines (Table 2A). The expression levels of the downstream members of RAS and BRAF are presented in Figure 1. In response to the constitutively activating BRAF mutation in Ocm 1, downstream members of the MAPK pathway show activation (phosphorylated MEK, ERK and ELK). Levels of expression of the downstream members were not different in the two cell lines derived from the same primary tumour (92.1 and 92.2), except for phosphorylated MEK, indicating that there had been little clonal divergence between the cell populations during *in vitro* culturing. Interestingly, compared to the phosphorylation status of these members in Ocm 1, most cell lines show activation of MEK, ERK and ELK; however, these cell lines show this activation in the absence of mutations in the upstream RAS and BRAF genes. The levels of total ERK were remarkably similar across all cell lines, with the exception of two cell lines Mel 285 and Mel 290, which had significantly higher levels of total ERK than the others. In keeping with this observation, these two cell lines also have the highest levels of phosphorylated-ERK. Figure 2 shows that there is no significant influence of serum on the activity of ERK1/2 in these cell lines, as reported recently by Calipel et al (2003).

**Immunohistochemistry**

Immunofluorescence results of total and phospho-ERK1/2 on a panel of 19 fresh frozen uveal melanoma sections are listed in Table 2 (B). In seven of the 19 primary tumours, less than 5% of the tumour cells stained positively for ERK1/2 and two nine tumours for phosphorylated ERK1/2. Despite the lack of mutations in the RAS and BRAF genes in this set of uveal melanomas, it is noteworthy that we observed phosphorylated (active) ERK1/2 expression in 10 of 19 tumours. There was no significant association between ERK1/2 activation and tumour location or cell type. The scoring system for each antibody cannot be compared between antibodies since the antibodies recognise different epitopes and with different affinities; therefore, the
staining intensity on Western or by immunohistochemistry is relative only to the other samples for the particular antibody used.

**DISCUSSION**

In the uveal melanoma cell lines and primary uveal melanomas analysed in our study, only cell line Ocm 1 carried a mutation in **BRAF** (V599E), thus confirming the documentation of a mutation in this cell line by Calipel et al (2003) and Kilic et al (2004). Similarly, our observation of a complete lack of **BRAF** mutations in primary uveal tumours mirrors the findings of several recent reports (Cohen et al, 2003; Cruz et al, 2003; Edmunds et al, 2003; Rimoldi et al, 2003; Weber et al, 2003; Kilic et al, 2004). Table 3 contains a summary of published reports on **RAS** and **BRAF** mutations, as well as studies on other members of the MAPK pathway, in uveal melanomas. Including the results of our study, to date not a single **BRAF** mutation has been found in a total of 276 primary or secondary uveal melanoma samples (Table 3). It is somewhat surprising therefore that three out of three uveal melanoma cell lines studied by Calipel et al (2003) carried the V599E mutation in **BRAF**, especially since only one out of 11 cell lines in the panel we analysed was found to have this mutation. Taken together, these data suggest that while a **BRAF** mutation is not required for uveal melanoma development *in vivo*, such mutations confer a cellular growth advantage and are hence selected if they occur in cell lines cultured *in vitro*.

In our study, none of the cell lines or primary tumours carried mutations in any of the three **RAS** genes (N, H and K), a finding consistent with a previous report (Soparker et al, 1993). These mutation data are in stark contrast to that for cutaneous melanoma, and would appear to suggest that the MAPK pathway is unlikely to play a significant role in uveal melanoma development. However, on the contrary, by Western blot analysis and immunohistochemistry, we have found substantial evidence for activation of the MAPK pathway, in the absence of serum, in the majority of uveal melanoma samples – both cell lines and primary uveal melanoma specimens. This frequent MAPK pathway

| Tumour sample ID | **BRAF** mutation analysis | **NRAS** mutation analysis | **KRAS** mutation analysis | **HRAS** mutation analysis | Total ERK1/2 IHC | Phospho ERK1/2 IHC |
|------------------|---------------------------|---------------------------|---------------------------|---------------------------|-----------------|-------------------|
| 1                | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 2                | WT                        | WT                        | WT                        | WT                        | +               | +++               |
| 3                | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 4                | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 5                | WT                        | WT                        | WT                        | WT                        | +               | +++               |
| 6                | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 7                | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 8                | WT                        | WT                        | WT                        | WT                        | +               | +++               |
| 9                | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 10               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 11               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 12               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 13               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 14               | WT                        | WT                        | WT                        | WT                        | +               | +++               |
| 15               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 16               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 17               | WT                        | WT                        | WT                        | WT                        | +               | +++               |
| 18               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |
| 19               | WT                        | WT                        | WT                        | WT                        | ++              | +++               |

Positive control cutaneous melanoma

V599E NA NA NA +++ ++++

The level of expression of the Western blotting and immunohistochemistry (IHC) experiments were scored and categorised as either negative (–), weakly positive (+), weakly moderately positive (++), moderately positive (+++) or strongly positive (++++)...
activation in uveal melanoma, independent of RAS and BRAF mutations, has also been reported recently by others (Rimoldi et al, 2003; Weber et al, 2003; ), but the mechanism is unknown. Recently, an interaction has been found between the MAPK and the PTEN pathways, both frequently activated in parallel to promote cutaneous melanoma development (Tsao et al, 2004). It is tempting to speculate that MAPK activation in uveal melanoma may arise via crosstalk with the PI3K/PTEN/AKT pathway, possibly as a consequence of mutation of some of its components (other than PTEN, which is not mutated in this tumour type). Thus, mutation analysis of the PI3K and AKT gene families in uveal melanomas seems warranted. Interestingly, Graells et al (2004) demonstrated that the proangiogenic vascular endothelial growth factor (VEGF), which is frequently highly expressed in

![Table 3](image)

**Table 3** Summary of published RAS and BRAF mutation studies in ocular melanoma

| Study                  | Sample type | BRAF mutation frequency | NRAS mutation frequency | KRAS mutation frequency | HRAS mutation frequency | Activation of other MAPK members |
|------------------------|-------------|-------------------------|-------------------------|-------------------------|-------------------------|----------------------------------|
| Mooy et al (1991)      | 1" tumours  | —                       | Codons 12,13,61 (0/29)  | —                       | —                       | —                                |
| Soparker et al (1993)  | 1" tumours  | —                       | Exon 1 (0/33)           | Exon 1 (0/36)           | 0/23                    | —                                |
| Edmunds et al (2003)   | 1" tumours  | 0/48                    | —                       | —                       | —                       | —                                |
| Cohen et al (2003)     | 1" tumours  | 0/29                    | —                       | —                       | —                       | Expression of MEK/ERK             |
| Rimoldi et al (2003)   | 1" tumours  | 0/10                    | —                       | —                       | —                       | —                                |
| Weber et al (2003)     | 1" tumours  | 0/42                    | 0/42                    | 0/42                    | —                       | Phospho-ERK (36/42) baseline expression ERK (42/42) |
| Cruz et al (Cancer Res.) | 2" tumours | 0/3                     | 0/3                     | 0/3                     | —                       | —                                |
| Calipel et al (2003)   | Cell lines  | 0/62                    | 0/62                    | 0/62                    | —                       | —                                |
| Kilic et al (2004)     | 1" tumours  | 0/33                    | —                       | —                       | —                       | —                                |
| This study             | 1" tumours  | 0/19                    | 0/19                    | 0/19                    | 0/19                    | High MEK/ERK levels              |
| Cell lines             | 1/10        | 0/10                    | 0/10                    | 0/10                    | 0/10                    | Activation MAPK pathway: MEK, ELK, ERK |

*Not specified if samples were from primary or secondary tumours. All V599E.

**Figure 1** Expression levels of members of the MAPK pathway downstream of RAS and BRAF in 11 uveal melanoma cell lines. Actin levels were assessed as a loading control.

**Figure 2** ERK1/2 and phospho-ERK1/2 expression in uveal melanoma cell lines (Mel 202, Ocm 1, Mel 285, Mel 290) cultured with (+) and without (−) serum (24 h). A similar lack of effect of serum on influencing the level of phospho-ERK1/2 was seen for each of the other uveal melanoma cell lines (data not shown).
uveal melanoma (Stitt et al., 1998; Sheidow et al., 2000), could operate in cutaneous melanoma as a survival factor through increasing MAPK and PI3K pathway activity. It is possible that MAPK activation is such a crucial requirement for uveal melanoma development because it similarly provides survival, and/or anti-apoptotic signals, necessary for tumour cell growth and maintenance.

Although many uveal melanoma samples have been studied for BRAF and NRAS mutations, few have been analysed for MAPK activation and there is the implicit assumption that this pathway is not involved in uveal melanoma genesis. Our study is the only study design providing mutation information on all RAS members and expression data on a wide range of participants in the MAPK pathway. Our data thus support the notion that activation of MAPK is indeed involved in the development of uveal melanoma, but occurs via a different mechanism(s) to that in the majority of cutaneous melanomas. This conclusion has significant ramifications for the development of rational therapies to treat uveal melanoma as it implies that general inhibitors of the pathway may still be effective even though the tumours do not have mutations of RAS or BRAF.

ACKNOWLEDGEMENTS

We thank Dr AD Singh for generously providing a panel of fresh frozen primary uveal melanoma specimens, Dr M Bernsen and P Rombout for the cutaneous melanoma sections (Department of Pathology, University Medical Centre Nijmegen) and Drs Ksander and Kan-Mitchell for providing some of the cell lines. This work was supported by the National Health and Medical Research Council of Australia, the ‘Rotterdamse Vereniging Blindenbelang’ and the ‘Landelijke Stichting voor Blinden en Slechtzienden’. FvN is supported by the Netherlands Organisation for Scientific Research and by the Dutch Cancer Society. NG is a recipient of an Aspasia fellowship of the Netherlands Organisation for Scientific Research.

REFERENCES

Alinsa J, Gorski DH, Germino FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait WN, Goydos JS (2003) Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 9: 6419 – 6425
Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gervino H, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997 – 7000
Calipel A, Lefevere G, Pouponnont C, Mouriaux E, Mascarilli F (2003) Mutation of B-Raf in human chordoid melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway: J Biol Chem 278: 42409 – 42418, doi:10.1074/jbc.M308709200
Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe’er J, Sidransky D (2003) Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44: 2876 – 2878, doi:10.1167/iovs.02-1329
Cohen Y, Rosenbaum B, Begum S, Goldenberg D, Eschke C, Lavey O, Sidransky D, Westra WH (2004) Exon 15 BRAF mutations are uncommon in melanomas arising in non-sun-exposed sites. Clin Cancer Res 10: 3444 – 3447
Cohen C, Zavala-Pompa A, Sequeira JH, Shiomi M, Sexton DG, Cotsonis G, Cohen Y, Rosenbaum B, Begum S, Goldenberg D, Eschke C, Lavey O, Sidransky D, Westra WH (2004) Exon 15 BRAF mutations are uncommon in melanomas arising in non-sun-exposed sites. Clin Cancer Res 10: 3444 – 3447
Cruz III F, Robin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Coless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63(18): 5761 – 5766
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dickens E, Ewing R, Floyd Y, Hall S, Hawes R, Hughes J, Kosmidou V, Mennes Z, Aoud C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations in uveal melanoma. Br J Cancer 89: 1509 – 1513
Dewaard-Siebinga I, Blom DJ, Griffoon M, Schirrer PJ, Hoogendoorn E, Beverstock G, Danen EH, Jager MJ (1995) Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 62: 155 – 161
Diener-West M, Hawkins BS, Markowitz JA, Schachat AP (1992) A review of mortality rates from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 110: 243 – 250
Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63(14): 3883 – 3885
Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurrun JS, Kelsell DP (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 88: 1403 – 1405, doi:10.1038/sj.bjc.6600919
Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D (2003) Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63(14): 3955 – 3957
Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marconval J, Gonzalez FJ, Fabra A (2004) Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123: 1151 – 1161
Guldberg P, thor Straten P, Birck A, Ahrenkuel V, Kirkin AF, Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660 – 3663
Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE (1989) Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 30: 829 – 834
Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooij NM, Luyten GP, De Klein A (2004) The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 14: 203 – 205
Kumar R, Angelini S, Czene K, Saurao I, Hakka-Kempinen M, Pyrhonen S, Hemminki K (2003a) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9: 3362 – 3368
Kumar R, Angelini S, Hemminki K (2003b) Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allicic loss on chromosome 9. Oncogene 22: 9217 – 9224, doi:10.1038/sj.onc.1206909
Luyten GP, Nauc NC, Mooi CM, Hagemeijer A, Kan-Mitchell J, van Drunen E, Vucevski V, de Jong PT, Luider TM (1996) Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer 66: 380 – 387, doi:10.1002/(sici)1097-0215
Maldonado IL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878 – 1890
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 16: 3444
Mool CM, de Jong PT (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41: 215 – 228
Mooy CM, Van der Helm MJ, Van der Kwast TH, de Jong PT, Ruiter DJ, Zwarthoff EC (1991) No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. Br J Cancer 64: 411 – 413
Naus NC, Zuidervaat W, Rayman N, Slater R, van Drunen E, Ksander B, Luyten GP, Klein A (2000) Mutation analysis of the PTFEN gene in uveal melanoma cell lines. Int J Cancer 87: 151 – 153
Naus NC, Zuidervaat W, Rayman N, Slater R, van Drunen E, Ksander B, Luyten GP, Klein A (2000) Mutation analysis of the PTFEN gene in uveal melanoma cell lines. Int J Cancer 87: 151 – 153
Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483 – 6488
Pollock FM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray
P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. *Nat Genet* 33: 19 – 20, doi:10.1038/ng1054

Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G (2004) Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. *Int J Cancer* 109: 377 – 384, doi:10.1002/ijc.11722

Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC (2003) Lack of BRAF mutations in uveal melanoma. *Cancer Res* 63: 5712 – 5715

Satyamoorthy K, Li G, Herrmann G, Volpe P, Van Belle P, Elder DE, Herlyn M (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. *J Invest Dermatol* 122: 337 – 341

Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP (2003) Loss of PTEN promotes tumor development in malignant melanoma. *Cancer Res* 63: 2881 – 2890

Stitt AW, Simpson DA, Boocock C, Gardiner TA, Murphy GM, Archer DB (1998) Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. *J Pathol* 186: 306 – 312

Chen Z, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. *J Invest Dermatol* 122: 337 – 341

van der Velden PA, Metzelaar-Blok JA, Bergman W, Hurks HMM, Frants RR, Gruis NA, Jager MJ (2001) Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. *Cancer Res* 61: 5303 – 5306

van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI (1996) Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. *Am J Pathol* 149: 883 – 893

Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohamadsaegh, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. *Lab Invest* 83: 1771 – 1776, doi:10.1097/01.LAB.000010732.89463.29

Yazdi AS, Lienard D, Speiser D, Zografos L, Cerottini JC (2003) Lack of BRAF mutations in uveal melanoma. *Cancer Res* 63: 5712 – 5715

Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. *Clin Cancer Res* 10: 1753 – 1757

Sidley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC (1997) Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. *Genes Chromosomes Cancer* 19: 22 – 28, doi:10.1002/(sici)1098-2264(199705)

Noparker CN, O'Brien JM, Albert DM (1993) Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. *Invest Ophthalmol Vis Sci* 34: 2203 – 2209

MAPK pathway activation in uveal melanoma